A Phase 2 Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter's Syndrome (RS)

被引：0
|
作者：
Crombie, Jennifer L. [1 ]
Ryan, Christine E. [2 ]
Ren, Yue [2 ]
Tyekucheva, Svitlana [3 ]
Carey, Celeste [4 ]
Zou, Aaron [4 ]
Normilus, Samantha [4 ]
Montegaard, Josie [4 ]
Soumerai, Jacob D. [5 ]
Bhandari, Shruti [6 ]
Arnason, Jon E. [7 ]
Alencar, Alvaro J. [8 ]
Kim, Austin I. [9 ]
Parry, Erin M. [2 ]
Armand, Philippe [2 ]
Fisher, David C. [2 ]
Brown, Jennifer R. [10 ]
Davids, Matthew S. [11 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA USA
[2] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA
[3] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA
[4] Dana Farber Canc Inst, Boston, MA USA
[5] Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA
[6] Northern Light Canc Care, Dept Hematol & Oncol, Brewer, ME USA
[7] Beth Israel Deaconess Med Ctr, Boston, MA USA
[8] Univ Miami, Sylvester Comprehens Canc Ctr, Miller Sch Med, Div Hematol, Miami Beach, FL USA
[9] Dana Farber Canc Inst, Dept Med Oncol, Newton Ctr, MA USA
[10] Dana Farber Canc Inst, Dept Med Oncol, Newton, MA USA
[11] Dana Farber Canc Inst Inc, Dept Med Oncol, Boston, MA USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-199234
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：4628 / 4629
页数：2
相关论文
共 50 条
  • [41] MINIMAL RESIDUAL DISEASE (MRD)-DRIVEN TREATMENT PERSONALIZATION WITH SEQUENTIAL ADDITION OF IBRUTINIB (IBR) TO VENETOCLAX (VEN) IN RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): THE IMPROVE STUDY
    Scarfo, L.
    Heltai, S.
    Albi, E.
    Scarano, E.
    Schiattone, L.
    Farina, L.
    Gaidano, G.
    Deodato, M.
    Ferrario, A.
    Motta, M.
    Reda, G.
    Sancetta, R.
    Coscia, M.
    Ladetto, M.
    Laurenti, L.
    Varettoni, M.
    Perotta, E.
    Capasso, A.
    Ranghetti, P.
    Colia, M.
    Ghia, P.
    HAEMATOLOGICA, 2021, 106 (10) : 4 - 4
  • [42] Effect of Dose Modifications on Response to Duvelisib in Patients with Relapsed/Refractory (R/R) CLL/SLL in the DUO Trial
    Flinn, Ian
    Montillo, Marco
    Illes, Arpad
    Etienne, Gabriel
    Delgado, Julio
    Kuss, Bryone
    Tam, Constantine
    Offner, Fritz
    Bosch, Francesc
    Davids, Matthew
    Jaeger, Ulrich
    Ghia, Paolo
    Cymbalista, Florence
    Weaver, David
    Lustgarten, Stephanie
    Youssoufian, Hagop
    Stilgenbauer, Stephan
    Lamanna, Nicole
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S273 - S274
  • [43] First Interim Analysis of ALPINE Study: Results of a Phase 3 Randomized Study of Zanubrutinib vs Ibrutinib in Patients With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
    Brown, Jennifer R.
    Hillmen, Peter
    Eichhorst, Barbara
    Lamanna, Nicole
    O'Brien, Susan
    Tam, Constantine S.
    Qiu, Lugui
    Kazmierczak, Maciej
    Zhou, Keshu
    Simkovic, Martin
    Mayer, Jiri
    Gillespie-Twardy, Amanda
    Shadman, Mazyar
    Ferrajoli, Alessandra
    Ganly, Peter S.
    Weinkove, Robert
    Salmi, Tommi
    Wu, Kenneth
    Novotny, William
    Jurczak, Wojciech
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S266 - S266
  • [44] Alpine: Phase 3 Trial of Zanubrutinib (BGB-3111) Vs Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
    Hillmen, Peter
    Brown, Jennifer R.
    Byrd, John C.
    Eichhorst, Barbara F.
    Lamanna, Nicole
    O'Brien, Susan M.
    Qiu, Lugui
    Salmi, Tommi
    Hilger, James
    Huang, Jane
    Tam, Constantine S.
    BLOOD, 2019, 134
  • [45] Phase 1b Results of a Phase 1b/2 Study of Obinutuzmab, Ibrutinib, and Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
    Jones, Jeffrey A.
    Woyach, Jennifer
    Awan, Farrukh T.
    Maddocks, Kami J.
    Whitlow, Thomas
    Ruppert, Amy S.
    Byrd, John C.
    BLOOD, 2016, 128 (22)
  • [46] Transcend CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
    Wierda, William G.
    Dorritie, Kathleen A.
    Munoz, Javier
    Stephens, Deborah M.
    Solomon, Scott R.
    Gillenwater, Heidi H.
    Gong, Lucy
    Yang, Lin
    Ogasawara, Ken
    Thorpe, Jerill
    Siddiqi, Tanya
    BLOOD, 2020, 136
  • [47] Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINE
    Zhou, Keshu
    Wang, Tingyu
    Pan, Ling
    Xu, Wei
    Jin, Jie
    Zhang, Wei
    Hu, Yu
    Hu, Jianda
    Feng, Ru
    Li, Ping
    Liu, Zhougang
    Liu, Peng
    Jing, Hongmei
    Gao, Sujun
    Zhang, Huilai
    Yu, Kang
    Wang, Zhao
    Zhu, Xiongpeng
    Sun, Zimin
    Li, Fei
    Yan, Dongmei
    Weng, Jianyu
    Fu, Lina
    Wang, Liping
    Salmi, Tommi
    Wu, Kenneth
    Qiu, Lugui
    ANNALS OF HEMATOLOGY, 2024, 103 (10) : 4183 - 4191
  • [48] Efficacy and Safety of Ibrutinib (IBR) after Venetoclax (VEN) Treatment in IBR-Naive Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Follow-up of Patients from the MURANO Study
    Greil, Richard
    Fraser, Graeme
    Leber, Brian
    Marks, Reinhard
    Quaresmini, Giulia
    Middeke, Jan Moritz
    Semenzato, Gianpietro
    Schary, William
    Boyer, Michelle
    Breuleux, Madlaina
    Crompton, Noelle
    Humphrey, Kathryn
    Marlton, Paula
    BLOOD, 2018, 132
  • [49] Comparison of Venetoclax Based Treatments for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
    Heyman, Benjamin M.
    Choi, Michael Y.
    Kipps, Thomas J.
    BLOOD, 2023, 142
  • [50] Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma
    Izutsu, Koji
    Yamamoto, Kazuhito
    Kato, Koji
    Ishikawa, Takayuki
    Fukuhara, Noriko
    Terui, Yasuhito
    Choi, Ilseung
    Humphrey, Kathryn
    Kim, Su Young
    Okubo, Sumiko
    Ogawa, Natsumi
    Nishimura, Yasuko
    Salem, Ahmed Hamed
    Maruyama, Dai
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 113 (03) : 370 - 380
12345